342 related articles for article (PubMed ID: 6373933)
61. Treatment of experimental visceral leishmaniasis with lymphokine encapsulated in liposomes.
Reed SG; Barral-Netto M; Inverso JA
J Immunol; 1984 Jun; 132(6):3116-9. PubMed ID: 6725947
[TBL] [Abstract][Full Text] [Related]
62. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A.
Fidler IJ; Darnell JH; Budmen MB
Cancer Res; 1976 Oct; 36(10):3608-15. PubMed ID: 953987
[TBL] [Abstract][Full Text] [Related]
63. [Activation of the production of the tumor-necrosis factor by the combined action of lipopolysaccharide and muramyl dipeptide in vitro and in vivo].
Fuks BB; Rakhmilevich AL; Pimenov AA; Dubrovskaia AG
Biull Eksp Biol Med; 1987 Oct; 104(10):497-9. PubMed ID: 3315036
[TBL] [Abstract][Full Text] [Related]
64. Comparative studies between liposomes containing muramyl dipeptide and various immunomodulators on activation of mouse peritoneal macrophages and NK cells.
Sakita M; Kageyama N; Majima S
Oncology; 1985; 42(4):259-64. PubMed ID: 4011111
[TBL] [Abstract][Full Text] [Related]
65. [The synergistic action of lipopolysaccharide and muramyl dipeptide in the immunotherapy of DBA/2 mice with mastocytoma P815].
Rakhmilevich AL; Rakhimova MS
Biull Eksp Biol Med; 1989 Dec; 108(12):721-4. PubMed ID: 2517487
[TBL] [Abstract][Full Text] [Related]
66. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease.
Fidler IJ; Poste G
Springer Semin Immunopathol; 1982; 5(2):161-74. PubMed ID: 6755782
[No Abstract] [Full Text] [Related]
67. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Fogler WE; Wade R; Brundish DE; Fidler IJ
J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
[TBL] [Abstract][Full Text] [Related]
68. Macrophage activation and generation of tumoricidal activity by liposome-associated human C-reactive protein.
Barna BP; Deodhar SD; Gautam S; Yen-Lieberman B; Roberts D
Cancer Res; 1984 Jan; 44(1):305-10. PubMed ID: 6690042
[TBL] [Abstract][Full Text] [Related]
69. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
Nagao S; Sato K; Osada Y
Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
[TBL] [Abstract][Full Text] [Related]
70. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
71. Production and utilization of human lymphokines containing macrophage-activating factor (MAF) activity.
Kleinerman ES; Fidler IJ
Lymphokine Res; 1983; 2(1):7-12. PubMed ID: 6381900
[No Abstract] [Full Text] [Related]
72. [Activation of the production of cytotoxic factors by mouse spleen cells exposed to the combined action of lipopolysaccharide and muramyl dipeptide in vitro].
Rakhmilevich AL; Rakhimova MS
Biull Eksp Biol Med; 1988 Apr; 105(4):483-6. PubMed ID: 3359036
[TBL] [Abstract][Full Text] [Related]
73. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.
BubenÃk J; Jezek J; Zaoral M; Hofmann J; Gruntenko YV; Osipov JG; Zolotareva AG; Vakhrusheva TE; Budker VG
Cancer Immunol Immunother; 1984; 18(2):123-5. PubMed ID: 6568871
[TBL] [Abstract][Full Text] [Related]
74. Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.
Brodt P; Blore J; Phillips NC; Munzer JS; Rioux JD
Cancer Immunol Immunother; 1989; 28(1):54-8. PubMed ID: 2909283
[TBL] [Abstract][Full Text] [Related]
75. Secretion of macrophage cytotoxic factors induced by new desmuramyl acylpseudopeptide analogs of muramyl dipeptide.
Breton P; Petit C; Bousser MT; Monsigny M; Mayer R; Roche AC
Oncol Res; 1992; 4(3):103-7. PubMed ID: 1617210
[TBL] [Abstract][Full Text] [Related]
76. Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease.
Poste G; Kirsh R
Prog Clin Biol Res; 1982; 102 pt A():309-19. PubMed ID: 7167443
[No Abstract] [Full Text] [Related]
77. Activation of tumoricidal properties in macrophages by lymphokines encapsulated in liposomes.
Fidler IJ; Fogler WE
Lymphokine Res; 1982; 1(3):73-7. PubMed ID: 6765335
[No Abstract] [Full Text] [Related]
78. Production of macrophage-activating factor by T lymphocyte clones and correlation with other lymphokine activities.
Kelso A; Glasebrook AL; Kanagawa O; Brunner KT
J Immunol; 1982 Aug; 129(2):550-6. PubMed ID: 7045227
[TBL] [Abstract][Full Text] [Related]
79. Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines.
Kleinerman ES; Schroit AJ; Fogler WE; Fidler IJ
J Clin Invest; 1983 Jul; 72(1):304-15. PubMed ID: 6348087
[TBL] [Abstract][Full Text] [Related]
80. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
Fogler WE; Fidler IJ
Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
